Claritas Pharmaceuticals adds Dr. Salvatore Cuzzocrea to its Board as Independent Director

– USA, CA –  Claritas Pharmaceuticals, Inc. (TSX: KLY | OTC: KALTF) today announced the addition of Professor Salvatore Cuzzocrea, Ph.D. to its Board as an independent director, effective immediately.

Dr. Cuzzocrea is an acknowledged expert in the science and clinical use of nitric oxide therapy, and his appointment to the Board of Directors will position the Company as a leader in the field of nitric oxide therapeutics.

“We are delighted to add Dr. Cuzzocrea to the Company’s Board of Directors,” said CEO, Robert Farrell. “We are eager to begin work with Dr. Cuzzocrea on development of R-107, our proprietary nitric oxide releasing compound that is being developed as a treatment for coronavirus, vaccine-resistant COVID-19, and other viral infections. With his deep experience and knowledge regarding nitric oxide and R-107, he will be a strong strategic resource for Claritas. We look forward to the contributions he will make.”

Dr. Cuzzocrea brings expert knowledge of R-107 to Claritas, having carried out more than 40 studies of this molecule in the treatment of experimental models of acute lung injury, pulmonary arterial hypertension, wound healing, ischemia-reperfusion injury, and multiple organ failure in sepsis and endotoxic shock. Dr. Cuzzocrea is an authority also on the biological mechanisms of cytokine-storm-induced acute lung injury and thus is ideally positioned to understand the pathophysiology of COVID-19 disease and its amelioration by the supplemental provision of nitric oxide by the administration of R-107.

Nitric oxide has been demonstrated to be effective against a wide variety of viruses. Nevertheless, nitric oxide has not been developed as an antiviral agent due to the fact that it is a gas that must be administered by inhalation therapy, which requires special inhalation equipment and administration by trained respiratory therapists. R-107 is a liquid, nitric oxide-releasing compound designed to overcome these issues. R-107 can be easily administered orally as a capsule, or nasally through use of a nasal spray, or by injection. Claritas will not only develop R-107 as a therapy for vaccine-resistant COVID-9 infection, but also as a broad-spectrum antiviral drug for the treatment and possible prevention of future viral outbreaks, including viruses that cause influenza and the common cold.

About Prof. Salvatore Cuzzocrea

Dr. Cuzzocrea, the former President of the European Shock Society, is an internationally renowned authority and leader on the biology and pathophysiology of nitric oxide. He currently serves in numerous leadership roles at the University of Messina in Sicily, including Director of Scientific Research, Director of the Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, Director of the Oncology Unit at the University Hospital of Messina, and Full Professor of Pharmacology at the University’s School of Medicine. Dr. Cuzzocrea has been awarded honorary Professorships in Pharmacology at the University of Manchester and Saint Louis University, was elected a Fellow of the British Pharmacological Society, and has been appointed as an Honorary Lecturer in Pharmacology at the Department of Experimental Medicine and Nephrology at The William Harvey Institute at St. Bartholomew’s and Royal London School of Medicine and Dentistry. In 2020, Professor Cuzzocrea was elected Vice-President of the Board of the Conference of Rectors of all Italian universities.

Dr. Cuzzocrea received his undergraduate and graduate medical education at the University of Messina, followed by doctoral studies at Cincinnati Children’s Hospital Medical Center and the William Harvey Institute in London. He is the author of more than 759 peer-reviewed publications and books, and is an international leader in the fields of autoimmunity, inflammation, toxic inhalational lung injury, and neurodegenerative disorders. Dr. Cuzzocrea’s research interests include the role of nitric oxide in the pathophysiology and treatment of pulmonary inflammation and cytokine storm associated acute lung injury, and the identification of new potential pharmacological targets for nitric oxide in autoimmune and inflammatory diseases.

About Claritas Pharmaceuticals

Claritas Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for patients with significant unmet medical needs. Claritas focuses on areas of unmet medical need, and leverages its expertise to find solutions that will improve health outcomes and dramatically improve people’s lives.

For more information :

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team